Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 12,649 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period A Clear all

Conditions: Thrombocytopenia
Interventions: Avatrombopag, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Ribavirin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • Fairfax, Virginia

Conditions: Sepsis
Interventions: Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 43
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more

Conditions: Chronic Pain, Back Pain Lower Back Chronic, Back Pain
Interventions: Virtual Reality Therapy for Chronic Pain; Device
Lead sponsor: CognifiSense Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Sezary Syndrome, Mycosis Fungoides
Interventions: Mogamulizumab, LD TSEBT; Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain, Hip Fracture
Interventions: Placebo, Acetaminophen IV; Drug
Lead sponsor: Lancaster General Hospital; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Liver Transplant Rejection
Interventions: CFZ533, Tacrolimus - MMF - corticosteroids; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
Interventions: MLN3126, MLN3126 Matched Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: Encino, California • Granada Hills, California • Mission Viejo, California + 9 more

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment; Drug
Lead sponsor: Clinical Research Center of the Carolinas; Other
Eligibility: 2 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Neonatal Abstinence Syndrome, Aromatherapy
Interventions: lavender and chamomile essential oils; Drug
Lead sponsor: John M. Daniel; Other
Eligibility: Up to 2 Weeks
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions: entinostat, Omeprazole, Famotidine; Drug · Dietary Supplement
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: HIV-1 Infection
Interventions: Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more

Conditions: Healthy Volunteers
Interventions: TAK-279, Erythromycin, Phenytoin, Efavirenz; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Atherosclerosis, Diabetes, Coronary Artery Disease
Interventions: Nicotinamide riboside (NR), Placebo; Dietary Supplement · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 39 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Shoulder Pain, Neck Pain
Interventions: Noxipoint Therapy, Physical Therapy; Procedure
Lead sponsor: Pain Cure Center, California; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Appendicitis
Interventions: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 25
States / cities: Sylmar, California • Torrance, California • Aurora, Colorado + 14 more

Conditions: Metabolic Content of Urine
Interventions: Urine sample, Sleep restriction; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Post Traumatic Stress Disorder, Diminished Pleasure, Anhedonia, PTSD, Chronic PTSD, Chronic Post-Traumatic Stress Disorder
Interventions: Cognitive Processing Therapy; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diffuse Intrinsic Pontine Glioma
Interventions: Bevacizumab, Erlotinib, Temozolomide, Radiation; Drug · Radiation
Lead sponsor: Karen D. Wright MD; Other
Eligibility: 3 Years to 18 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 116
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 56 more

Conditions: Leukemia
Interventions: imatinib mesylate, gene expression analysis, mutation analysis, polymerase chain reaction, flow cytometry, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 4
States / cities: Buffalo, New York • Durham, North Carolina • Cleveland, Ohio

Conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions: Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training, Short-Term Fasting; Behavioral · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced Urothelial Carcinoma
Interventions: capivasertib; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 4
States / cities: West Haven, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more

Search by objective public record fields.

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Vitamin C, Thiamine, and Steroids in Sepsis

Virtual Reality Treatment for Adults With Chronic Back Pain

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

Noxipoint Therapy Versus Standard Physical Therapy Using Electrical Stimulation for Chronic Pain

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

Study of Metabolic Content of Urine

Psychotherapy Effects on Reward Processing in PTSD

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer